Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 3/20 | 0.54 |
| ▸ | FAAH | O00519 | 7/20 | 0.52 |
| ▸ | MGLL | Q99685 | 3/20 | 0.52 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.48 |
| ▸ | RPA1 | P27694 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | BCL2 | P10415 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2193884 | 0.94 | TP53 (0.52) | CA9FAAHMGLLCHRNA7KDM4E | |
| SCHEMBL1765262 | 0.93 | TP53 (0.52) | CA9FAAHMGLLCHRNA7KDM4E | |
| SCHEMBL1765446 | 0.91 | CHRNA7 (0.49) | CA9FAAHMGLLCHRNA7GAA | |
| SCHEMBL1765512 | 0.88 | CA9 (0.50) | CA9FAAHMGLLCHRNA7KDM4E | |
| SCHEMBL1765367 | 0.87 | CHRNA7 (0.50) | CA9FAAHMGLLCHRNA7RPA1 | |
| SCHEMBL1765280 | 0.87 | CHRNA7 (0.50) | CA9FAAHMGLLCHRNA7RPA1 | |
| SCHEMBL1765413 | 0.86 | CHRNA7 (0.47) | CA9FAAHMGLLCHRNA7RPA1 | |
| SCHEMBL3831473 | 0.86 | ALDH1A1 (0.46) | CA9FAAHMGLLGAAKMT2A | |
| SCHEMBL3834923 | 0.84 | KMT2A (0.49) | GAAKMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL1764971 | 0.83 | TP53 (0.48) | CA9FAAHMGLLCHRNA7KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399682-B2 | Substituted (pyrazolylcarbonyl)imidazolidinones and their use | AICURIS GMBH & CO. KG (DE) | 2013-03-19 | — | — | US | disclosed |
| US-8399682-B2 | Substituted (pyrazolylcarbonyl)imidazolidinones and their use | AICURIS GMBH & CO. KG (DE) | 2013-03-19 | — | — | US | disclosed |
| US-8399682-B2 | Substituted (pyrazolylcarbonyl)imidazolidinones and their use | AICURIS GMBH & CO. KG (DE) | 2013-03-19 | — | — | US | disclosed |
| US-20110124618-A1 | SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE | AICURIS GMBH & CO. KG (DE) | 2011-05-26 | — | — | US | disclosed |
| US-20110124618-A1 | SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE | AICURIS GMBH & CO. KG (DE) | 2011-05-26 | — | — | US | disclosed |
| US-20110124618-A1 | SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE | AICURIS GMBH & CO. KG (DE) | 2011-05-26 | — | — | US | disclosed |
| WO-2009115213-A1 | (PYRAZOLYL CARBONYL)IMIDAZOLIDINONE DERIVATIVES FOR THE TREATMENT OF RETROVIRAL DISEASES | AICURIS GMBH & CO. KG (DE) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124618-A1 | SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE | TPMT, PAICS, THPO | CA9 4825/4885FAAH 4725/4885MGLL 4676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.